Charmacy Pharmaceutical Co. Ltd. has announced the renewal of its continuing connected transactions through the signing of a New Framework Loan Agreement with Jiangyao, the company's controlling shareholder. The new agreement, effective from January 1, 2026, grants Charmacy access to a loan facility with a maximum limit authorized by statutory approval authorities for a term of three years. The agreement is designed to provide scalable, stable, and reliable funding to support the Group's operational needs and strategic growth opportunities. The terms, including interest rates, are determined following arm's length negotiations and are benchmarked against market rates offered by leading commercial banks to ensure fairness and competitiveness. The multi-level approval process within the company further ensures that the terms are no less favorable than those available from independent third parties.